JD Health International Inc. (06618) witnessed a notable upswing, with shares climbing nearly 4% to HK$45.2 during trading, reflecting a robust turnover of HK$385 million. This surge follows the formal signing of a strategic cooperation agreement between JD Health and Innovent Biologics. The partnership will foster deep collaboration across critical areas such as pharmaceutical supply, omni-channel sales, and digital marketing, integrating their core strengths to deliver diverse, high-quality medicines and health services to consumers. Jin Enlin, CEO of JD Health, articulated the company's dedication to ensuring effective medications reach patients efficiently. He emphasized leveraging technology to empower the healthcare sector, driving more equitable and intelligent allocation of medical resources. Enlin expressed optimism about expanding joint efforts into disease domains like oncology and chronic illnesses, using this pact as a springboard for future innovation. Adding to the momentum, UBS projected JD Health's second-quarter revenue growth to hit 17% to 19% year-over-year, implying first-half expansion exceeding 20%—well above the market consensus of 18.6%. Concurrently, UBS foresees sustained quarterly gross margin improvements, fueled by widening product sales profitability and vigorous advertising revenue gains. Nomura echoed this bullish sentiment, forecasting that JD Health's first-half revenue and earnings could outperform expectations, signaling strong operational health.